Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Va Medical Center

Neither a doctor nor a teaching hospital

Research payments

$1,075,310

63 payments

Through program year 2025, Va Medical Center is reported as receiving $1,075,310 in research payments, across 63 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $407,742 7
2024 Research $88,145 1
2023 Research $325,952 6
2022 Research $44,497 19
2021 Research $39,209 6
2020 Research $69,772 10
2019 Research $99,992 14

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $926,213 27 payments
  2. E.R. Squibb & Sons, L.L.C. $61,543 3 payments
  3. KARL STORZ Endoscopy-America $32,040 7 payments
  4. Celgene Corporation $19,385 4 payments
  5. Medtronic, Inc. $13,500 1 payment
  6. Boehringer Ingelheim International GmbH $10,300 5 payments
  7. Boston Scientific Corporation $5,463 12 payments
  8. Medtronic Vascular, Inc. $4,313 3 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $2,553 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. An Open-Label, Randomized, Phase III Study Comparing 177Lu-Psma-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (Mhspc) $796,486 8 payments
  2. Prospective Comparison of Arni With Arb Given Following Stabilization in Decompensated Hfpef (Paraglide-Hfpef) $77,330 6 payments
  3. A Master Protocol of Phase II Studies of Nivolumab in Advanced NSCLC Nivolumab as Maintenance after Induction Chemotherapy or as First Line Treatment, Alone or in Combination of Standard of Care Therapies $58,203 2 payments
  4. Blue Light Flexible Cystoscopy with Cysview Study $32,040 7 payments
  5. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Finding Study To Evaluate The Efficacy and Safety Of CC-90001 In Subjects With Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis $17,694 1 payment
  6. Two Arm Randomized Phase 3 Study in High Risk Nsclc Comparing Canakinumab VS Placebo in Adjuvant Setting $14,492 1 payment
  7. Prevail Global $13,500 1 payment
  8. A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Multicenter Study of Intravenous Secukinumab to Compare Efficacy at 16 Weeks With Placebo and to Assess Safety and Tolerability Up to 52 Weeks in Subjects With Active Ankylosing Spo $11,736 2 payments
  9. Observational Registry of Treatment Patterns in US Heart Failure Patients With Reduced Ejection Fraction $11,060 2 payments
  10. Empa-Kidney $10,300 5 payments
What the money was spent on Research payments · program years 2019–2025
  1. Other $20,608 5 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record